Short Interest in Lantheus Holdings, Inc. (NASDAQ:LNTH) Decreases By 18.3%

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 3,740,000 shares, a decrease of 18.3% from the July 15th total of 4,580,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the days-to-cover ratio is currently 3.5 days.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LNTH. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. SVB Leerink raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, JMP Securities dropped their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Lantheus Stock Performance

Shares of LNTH stock traded down $0.19 on Friday, reaching $94.91. The stock had a trading volume of 488,780 shares, compared to its average volume of 1,062,541. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.55 and a current ratio of 4.68. The company has a 50 day simple moving average of $95.35 and a 200 day simple moving average of $76.27. The stock has a market cap of $6.58 billion, a P/E ratio of 14.49 and a beta of 0.51. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s revenue was up 22.5% compared to the same quarter last year. During the same period last year, the company earned $1.40 earnings per share. Equities research analysts expect that Lantheus will post 6.46 EPS for the current year.

Insider Activity

In other news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold a total of 72,439 shares of company stock worth $6,432,198 over the last 90 days. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in Lantheus in the 4th quarter valued at approximately $407,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Lantheus by 2.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,888 shares of the medical equipment provider’s stock valued at $1,915,000 after purchasing an additional 809 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Lantheus in the fourth quarter worth $1,190,000. Strs Ohio lifted its stake in Lantheus by 12.1% during the fourth quarter. Strs Ohio now owns 7,400 shares of the medical equipment provider’s stock worth $458,000 after purchasing an additional 800 shares during the last quarter. Finally, Avior Wealth Management LLC boosted its position in Lantheus by 5.6% during the 4th quarter. Avior Wealth Management LLC now owns 5,858 shares of the medical equipment provider’s stock valued at $363,000 after purchasing an additional 309 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.